MiNK Reports First Quarter 2024 Results

2 years ago

Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American…

Alimera Sciences Reports First Quarter 2024 Results

2 years ago

Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024…

Entourage Health to Hold First Quarter 2024 Financial Results Call on May 28

2 years ago

Financial filings are expected after the market closes on May 27, and a management conference call will follow the next…

Scorpius Holdings, Inc. Announces Pricing of Public Offering

2 years ago

DURHAM, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated…

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

2 years ago

RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data…

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

2 years ago

Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to…

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

2 years ago

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II…

Strawberry Fields REIT Announces First Quarter 2024 Operating Results

2 years ago

South Bend, Indiana--(Newsfile Corp. - May 14, 2024) - Strawberry Fields REIT, Inc. (NYSE American: STRW) (the "Company") reported today…

Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies

2 years ago

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity

2 years ago

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the…